HK1095092A1 - Amino substituted diaryl [a,d] cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders - Google Patents

Amino substituted diaryl [a,d] cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders

Info

Publication number
HK1095092A1
HK1095092A1 HK07102395.0A HK07102395A HK1095092A1 HK 1095092 A1 HK1095092 A1 HK 1095092A1 HK 07102395 A HK07102395 A HK 07102395A HK 1095092 A1 HK1095092 A1 HK 1095092A1
Authority
HK
Hong Kong
Prior art keywords
analogs
methods
cycloheptene
treatment
amino substituted
Prior art date
Application number
HK07102395.0A
Other languages
English (en)
Inventor
Fredrik Ek
Roger Olsson
Jorgen Ohlsson
Original Assignee
Acadia Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acadia Pharm Inc filed Critical Acadia Pharm Inc
Publication of HK1095092A1 publication Critical patent/HK1095092A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/38—[b, e]- or [b, f]-condensed with six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
HK07102395.0A 2003-12-22 2007-03-05 Amino substituted diaryl [a,d] cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders HK1095092A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US53192703P 2003-12-22 2003-12-22
US54809004P 2004-02-24 2004-02-24
US54860404P 2004-02-27 2004-02-27
PCT/US2004/043224 WO2005063254A2 (en) 2003-12-22 2004-12-21 Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders

Publications (1)

Publication Number Publication Date
HK1095092A1 true HK1095092A1 (en) 2007-04-27

Family

ID=34743692

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07102395.0A HK1095092A1 (en) 2003-12-22 2007-03-05 Amino substituted diaryl [a,d] cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders

Country Status (23)

Country Link
US (5) US7550454B2 (es)
EP (2) EP1696931B1 (es)
JP (1) JP2007534656A (es)
KR (1) KR101157881B1 (es)
CN (1) CN101962369A (es)
AT (1) ATE426405T1 (es)
AU (1) AU2004308955B2 (es)
BR (1) BRPI0417749A (es)
CA (1) CA2550735A1 (es)
CY (1) CY1109171T1 (es)
DE (1) DE602004020263D1 (es)
DK (1) DK1696931T3 (es)
ES (1) ES2324713T3 (es)
HK (1) HK1095092A1 (es)
IL (1) IL176447A0 (es)
MX (1) MXPA06007244A (es)
NO (1) NO20063371L (es)
NZ (1) NZ547911A (es)
PL (1) PL1696931T3 (es)
PT (1) PT1696931E (es)
SG (1) SG133606A1 (es)
SI (1) SI1696931T1 (es)
WO (1) WO2005063254A2 (es)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1263729B1 (en) 2000-03-06 2006-12-20 Acadia Pharmaceuticals Inc. Azacyclic compounds for use in the treatment of serotonin related diseases
US6911452B2 (en) 2001-12-28 2005-06-28 Acadia Pharmaceuticals Inc. Spiroazacyclic compounds as monoamine receptor modulators
IL164155A0 (en) * 2002-03-20 2005-12-18 Teva Pharma Crystalline forms of quetiapine hemifumarate
MXPA04012893A (es) 2002-06-24 2005-03-31 Acadia Pharm Inc Derivados de piperidina n-substituidos como agentes receptores de serotonina.
US7538222B2 (en) 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
US7253186B2 (en) 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
KR101095939B1 (ko) 2003-01-16 2011-12-19 아카디아 파마슈티칼스 인코포레이티드 신경퇴행성 질환에 대한 치료제로서 선택적 세로토닌2ａ／2ｃ 리셉터 역작용제
US20050085463A1 (en) * 2003-01-23 2005-04-21 Weiner David M. Use of N-desmethylclozapine to treat human neuropsychiatric disease
AU2004206931A1 (en) * 2003-01-23 2004-08-05 Acadia Pharmaceuticals Inc. Use of N-desmethylclozapine to treat human neuropsychiatric disease
US20050250767A1 (en) * 2003-01-23 2005-11-10 Weiner David M Use of N-desmethylclozapine to treat human neuropsychiatric disease
NZ527142A (en) 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
WO2008021463A2 (en) * 2006-08-15 2008-02-21 Acadia Pharmaceuticals, Inc. Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
DE602004020263D1 (de) 2003-12-22 2009-05-07 Acadia Pharm Inc Amino-substituierte diaryläa,dücyclohepten- analoga als muscarinische agonisten und verfahren zur behandlung von neuropsychiatrischen erkrankungen
US20090239840A1 (en) * 2003-12-22 2009-09-24 Acadia Pharmaceuticals, Inc. AMINO SUBSTITUTED DIARYL[a,d]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
JP2007536216A (ja) * 2004-04-01 2007-12-13 アカディア ファーマシューティカルズ，インコーポレーテッド 固体ｎ−デスメチルクロザピンおよびその結晶形を合成および単離する方法
US20050261278A1 (en) * 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
US7820695B2 (en) 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
US7786141B2 (en) 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
WO2006023852A2 (en) 2004-08-19 2006-03-02 Vertex Pharmaceuticals, Incorporated Modulators of muscarinic receptors
US20060081361A1 (en) * 2004-09-13 2006-04-20 Gabbey Lawrence W Oil cooler with integral filter
AU2005289635A1 (en) * 2004-09-27 2006-04-06 Acadia Pharmaceuticals Inc. Salts of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide and their preparation
US7790899B2 (en) 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
KR20070086756A (ko) * 2004-11-29 2007-08-27 버텍스 파마슈티칼스 인코포레이티드 무스카린성 수용체의 조절제
EP1838325A1 (en) * 2005-01-07 2007-10-03 AstraZeneca AB NEW USE OF 11-PIPERAZIN-1-YLDIBENZO [b,f][1,4]THIAZEPINE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AND TO ORAL PHARMACEUTICAL COMPOSITIONS
US20060252744A1 (en) * 2005-04-04 2006-11-09 Burstein Ethan S Use of N-desmethylclozapine and related compounds as dopamine stabilizing agents
WO2006113425A1 (en) * 2005-04-14 2006-10-26 Teva Pharmaceutical Industries Ltd. Process for preparing quetiapine fumarate
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
US20080090805A1 (en) * 2005-10-17 2008-04-17 Acadia Pharmaceuticals Inc. Cb-1 modulating compounds and their use
WO2007047737A1 (en) * 2005-10-17 2007-04-26 Acadia Pharmaceuticals Inc. Cb-1 modulating compounds and their use
US20070106074A1 (en) * 2005-10-17 2007-05-10 Roger Olsson Iron catalyzed cross-coupling reactions of imidoyl derivatives
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070105836A1 (en) * 2005-10-31 2007-05-10 Lars Pettersson Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
WO2007056388A2 (en) * 2005-11-07 2007-05-18 The General Hospital Corporation Compositions and methods for modulating poly (adp-ribose) polymerase activity
WO2007062336A2 (en) * 2005-11-18 2007-05-31 Astrazeneca Ab Salt forms
WO2008079848A1 (en) * 2006-12-20 2008-07-03 Astrazeneca Ab (Se/Se) Compounds and uses thereof
US20090069292A1 (en) * 2005-11-18 2009-03-12 Astrazeneca Ab Liquid Formulations
CN101426499A (zh) * 2006-02-22 2009-05-06 弗特克斯药品有限公司 毒蕈碱受体调节剂
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2037918A2 (en) * 2006-05-15 2009-03-25 Acadia Pharmaceuticals Inc. Pharmaceutical formulations of pimavanserin
DE102006032426A1 (de) * 2006-07-13 2008-01-17 Neuraxpharm Arzneimittel Gmbh U. Co. Kg Verwendung von Zusammensetzungen von Clozapin, Quetiapin, schwer oder sehr schwer löslichen Säureadditionssalzen von Quetiapin und/oder Olanzapin zur Herstellung von Lösungen zur oralen Verabreichung
DE102006032427A1 (de) * 2006-07-13 2008-01-17 Neuraxpharm Arzneimittel Gmbh U. Co. Kg Verwendung von Zusammensetzungen von Clozapin, Quetiapin, schwer oder sehr schwer löslichen Säureadditionssalzen von Quetiapin und/oder Olanzapin zur Herstellung von Lösungen zur oralen Verabreichung
EP2051715A2 (en) * 2006-08-18 2009-04-29 Vertex Pharmceuticals Incorporated Modulators of muscarinic receptors
WO2008030651A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008118141A2 (en) * 2006-10-17 2008-10-02 Acadia Pharmaceuticals Inc. Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy
US20100016284A1 (en) * 2006-12-20 2010-01-21 Astrazeneca Ab Compounds and uses thereof - 151
GB0701970D0 (en) * 2007-02-01 2007-03-14 Wilson Stuart Treatment of protein aggregation diseases
RU2469033C2 (ru) * 2007-03-15 2012-12-10 Арикс Терапьютикс, Инк. СОЕДИНЕНИЯ ДИБЕНЗО[b,f][1,4]ОКСАЗАПИНА
CN101677971A (zh) 2007-03-19 2010-03-24 阿卡蒂亚药品公司 5-ht2a反向激动剂和拮抗剂与抗精神病药物的组合
JP2010540640A (ja) * 2007-10-03 2010-12-24 バーテックス ファーマシューティカルズ インコーポレイテッド ムスカリン作用性レセプターのモジュレーター
US8686158B2 (en) 2008-06-05 2014-04-01 President And Fellows Of Harvard College High-valent palladium fluoride complexes and uses thereof
NZ590616A (en) 2008-06-20 2012-09-28 Astrazeneca Ab Dibenzothiazepine derivatives and use thereof
WO2010062565A1 (en) * 2008-10-27 2010-06-03 Acadia Pharmaceuticals Inc. Muscarinic agonists
KR20110095898A (ko) 2008-11-20 2011-08-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 유기 화합물의 플루오르화
EP2385944A4 (en) * 2009-01-09 2013-06-19 Harvard College FLUORINATED COMPOUNDS AND METHODS OF USE
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CN101531570B (zh) * 2009-04-17 2012-10-10 中国科学院上海有机化学研究所 1，2-取代-5-乙炔基-(或10，11-二氢)-5H-二苯基[a，d]环庚烯(烷)-5-醇、合成方法及用途
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
HUE044653T2 (hu) 2009-07-22 2019-11-28 PureTech Health LLC Készítmények olyan rendellenességek kezelésére, amelyek muszkarin-receptor aktiválással enyhíthetõk
WO2011025748A1 (en) * 2009-08-26 2011-03-03 Acadia Pharmaceuticals, Inc. Amino substituted diaryl [a, d] cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
US9150516B2 (en) 2011-04-12 2015-10-06 President And Fellows Of Harvard College Fluorination of organic compounds
WO2014052622A1 (en) 2012-09-26 2014-04-03 President And Fellows Of Harvard College Nickel fluorinating complexes and uses thereof
JP6863742B2 (ja) * 2013-09-11 2021-04-21 ジ・アドミニストレーターズ・オブ・ザ・チューレーン・エデュケーショナル・ファンド 新規アントラニルアミドとその使用
WO2015058047A2 (en) 2013-10-18 2015-04-23 President And Fellows Of Harvard College Fluorination of organic compounds
CN104016937B (zh) * 2014-05-09 2016-12-07 中科院广州化学有限公司 一种n-芳基氧氮杂卓酮类化合物及其制备方法
TW202108592A (zh) * 2015-07-02 2021-03-01 瑞士商赫孚孟拉羅股份公司 苯并氧氮呯噁唑啶酮化合物及其用途
SI3325444T1 (sl) 2015-07-20 2021-11-30 Acadia Pharmaceuticals Inc. Postopki za pripravo N-(4-fluorobenzil)-N-(1-metilpiperidin-4-il)-N'- (4-(2-metilpropiloksi)fenilmetil)karbamida in njegove tartratne soli in polimorfne oblike C
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
WO2018118626A1 (en) 2016-12-20 2018-06-28 Acadia Pharmaceuticals Inc. Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
TW201831462A (zh) * 2017-01-25 2018-09-01 日商大日本住友製藥股份有限公司 二苯并二氮呯衍生物
WO2018148529A1 (en) * 2017-02-10 2018-08-16 Florida A&M University Identification of agents displaying functional activation of dopamine d2 and d4 receptors
US11135211B2 (en) 2017-04-28 2021-10-05 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
EP3675827A1 (en) 2017-08-30 2020-07-08 Acadia Pharmaceuticals Inc. Formulations of pimavanserin
AU2018346358A1 (en) 2017-10-06 2020-04-09 Leyden Technologies B.V. Stable solutions of multicyclic antidepressants
CN107903244B (zh) * 2017-11-29 2019-06-14 武汉珈创生物技术股份有限公司 具有抗肿瘤活性的2-胺基取代苯并二氮卓化合物及其制备方法
US11911351B2 (en) 2018-01-30 2024-02-27 Apnimed, Inc. (Delaware) Methods for treating sleep apnea with combinations of atomoxetine and (R)-oxybutynin
JP2021104931A (ja) * 2018-02-22 2021-07-26 大日本住友製薬株式会社 含窒素複素環を有するジベンゾアゼピン誘導体
CN110627735A (zh) * 2018-06-25 2019-12-31 江阴安博生物医药有限公司 一种新的喹硫平类似物及其制备方法和应用
MX2021003621A (es) 2018-09-28 2022-04-13 Karuna Therapeutics Inc Composiciones y metodos para tratar trastornos mejorados por medio de activacion de receptor muscarinico.
IL292370A (en) 2019-10-21 2022-06-01 Alairion Inc Pimerazine-converted azapine histories and their uses
CN112358455B (zh) * 2020-11-16 2022-07-19 吉林奥来德光电材料股份有限公司 一种二苯并七元杂环类化合物及其制备方法与应用
TWI820605B (zh) * 2022-02-18 2023-11-01 國立臺灣大學 抗菌化合物、其製備方法及其用途

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR870763A (fr) * 1939-12-19 1942-03-24 Zeiss Ikon Ag Procédé destiné à faire disparaître les bruits produits par les boucles du film dans les appareils de prise de vues et de reproduction, en particulier pour la priseet la reproduction de films sonores
CH240228A (de) * 1944-07-28 1945-12-15 Ciba Geigy Schaumisoliermasse auf Kunstharzbasis.
FR939591A (fr) 1946-01-09 1948-11-18 Philips Nv Récepteur de télévision
FR939595A (fr) * 1947-01-08 1948-11-18 Perfectionnements apportés aux tuiles à recouvrement en matériaux de toute nature
FR51M (es) 1960-06-03 1960-11-28
CH422793A (de) * 1961-07-20 1966-10-31 Wander Ag Dr A Verfahren zur Herstellung 11-basisch substituierter Dibenzo(b,f) (1,4)thiazepine
FR1334944A (fr) * 1961-08-11 1963-08-16 Wander Ag Dr A Procédé de préparation d'amidines de la série des 5-dibenzo-[b,e] [1,4]-diazépines
DE1620711A1 (de) * 1962-05-25 1970-06-04 Wander Ag Dr A Verfahren zur Herstellung 11-basisch substituierter 5H-Dibenzo[b,e][1,4]diazepine
CH476743A (de) * 1962-06-08 1969-08-15 Wander Ag Dr A Verfahren zur Herstellung von Amidinen der Dibenzo (b,e) (1,4)-diazepin-Reihe
NL140242B (nl) * 1963-03-01 1973-11-15 Wander Ag Dr A Werkwijze voor het bereiden van op de 11-plaats door een basische groep gesubstitueerde dibenz (b.f.)(1.4) oxazepinen.
GB1006156A (en) 1963-06-14 1965-09-29 Wander Ag Dr A 6-basic substituted morphanthridines
US3389139A (en) 1963-06-14 1968-06-18 Wander Ag Dr A 6-homopiperazino and piperazinomorphanthridines
US3884920A (en) 1967-07-14 1975-05-20 Sandoz Ag 11-Basically substituted dibenz {8 b,f{9 {0 {8 1,4{9 {0 oxazepines
US3908010A (en) 1967-03-22 1975-09-23 Wander Ag Dr A Basically substituted heterocycles as anti-emetics
AT258912B (de) 1964-05-27 1967-12-27 Wander Ag Dr A Verfahren zur Herstellung neuer 11-basisch substituierter Dibenz [b,f] [1,4]oxazepine
US3412193A (en) 1965-12-13 1968-11-19 American Cyanamid Co 11-(4-methyl-1-piperazinyl)dibenz[b, f][1, 4]oxazepines or thiazepines for controlling fertility
AT278805B (de) 1966-01-17 1970-02-10 American Cyanamid Co Verfahren zur herstellung von oxazepinen und thiazepinen
GB1184251A (en) 1966-04-15 1970-03-11 American Cyanamid Co Oxazepines and Thiazepines
GB1192812A (en) 1966-05-20 1970-05-20 American Cyanamid Co 2-Chloro-11-(1-Piperazinyl)Dibenz[b,f]-[1,4]Oxazepine, Non-Toxic Acid Addition Salts thereof, and Therapeutic Compositions containing said Oxazepine or Salts
NL6715650A (es) * 1966-12-16 1968-06-17
GB1177957A (en) 1966-12-23 1970-01-14 American Cyanamid Co Production of Oxazepines and Thiazepines
CA979441A (en) 1967-02-27 1975-12-09 American Cyanamid Company 11-(piperazinyl) dibenz (b,f) (1,4) oxazepines and analogous thiazepines
US3852446A (en) 1967-03-13 1974-12-03 Sandoz Ag Organic compounds in treatment of psychotic disturbances
CH514612A (de) 1967-03-13 1971-10-31 Wander Ag Dr A Verfahren zur Herstellung 11-basisch substituierter Dibenz(b,f)-1,4-oxazepine und Dibenzo(b,e)-1,4-diazepine
DE1720007A1 (de) * 1967-03-13 1971-05-19 Wander Ag Dr A Basisch substituierte Heterocyclen
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US3751415A (en) 1967-03-22 1973-08-07 Sandoz Ag 2-nitro-11-(1-piperazinyl)-dibenz(b,f)(1,4)oxazepines
US3758479A (en) 1967-03-22 1973-09-11 Sandoz Ag Nitro and sulphamoyl substituted dibenzodiazepines
CA918659A (en) 1969-07-31 1973-01-09 Yoshitomi Pharmaceutical Industries 11-(4-substituted-1-piperazinyl)-dibenzo (b,f) (1,4) thiazepines
NL7110453A (es) 1970-08-06 1972-02-08 Wander Ag Dr A
US3660406A (en) 1970-10-26 1972-05-02 American Cyanamid Co 2-chloro-7-hydroxy-11-(1-piperazinyl)dibenz(b f)(1 4)oxazepines
CH555856A (de) 1971-05-04 1974-11-15 Hoffmann La Roche Verfahren zur herstellung von tricyclischen verbindungen.
US3962248A (en) 1972-04-04 1976-06-08 Sandoz, Inc. Process for making 11-piperazino-diazepines, oxazepines, thiazepines and azepines
CH569730A5 (es) * 1972-04-04 1975-11-28 Wander Ag Dr A
CH585222A5 (en) 1973-02-14 1977-02-28 Wander Ag Dr A Prepn. of antipsychotic heterocyclic piperazine derivs. - by reaction of heterocyclic ketones with metal piperazine complexes
NL7403657A (es) 1973-03-23 1974-09-25
US3983234A (en) 1974-07-04 1976-09-28 Sandoz Ltd. Treatment of dyskinesias
DE2625258A1 (de) * 1975-06-06 1976-12-09 Hoffmann La Roche Dibenzo eckige klammer auf b,f eckige klammer zu thiepinderivat
FI762646A (es) * 1975-09-24 1977-03-25 Sandoz Ag
US4045445A (en) 1975-12-14 1977-08-30 American Cyanamid Company 11-(4-Piperidyl)dibenzo-diazepines
CS179793B1 (en) 1976-02-13 1977-11-30 Miroslav Protiva Biological derivative of 11-/4-methylpiperazino/-5h-dib)nzo/b,e/-1,4-diazepine
CH601288A5 (en) * 1976-06-09 1978-07-14 Sandoz Ag 11-Piperazino-5H-di:benzodiazepine derivs.
CH624682A5 (es) 1976-11-10 1981-08-14 Sandoz Ag
US4406900A (en) 1976-11-10 1983-09-27 Sandoz Ltd. Neuroleptic use of morphanthridines
US4096261A (en) * 1977-02-23 1978-06-20 Abbott Laboratories Dibenzodiazepines
US4191760A (en) 1977-02-23 1980-03-04 Abbott Laboratories Dibenzodiazepines
US4097597A (en) * 1977-02-23 1978-06-27 Abbott Laboratories Dibenzo b,e! 1,4!diazepines
DD133235A1 (de) * 1977-10-10 1978-12-20 Carla Rueger Verfahren zur herstellung von in 11-stellung basisch substituierten 5h-dibenzo eckige klammer auf b,e eckige klammer zu eckige klammer auf 1,4 eckige klammer zu diazepinen
CS196893B1 (en) 1977-12-22 1980-04-30 Miroslav Protiva 3-fluor-10-piperazino-8-substituted 10,11-dihydro-dibenzothiepines
US4263207A (en) 1978-08-01 1981-04-21 Merck & Co., Inc. 10,11-Dihydrodibenzo[b,f][1,4]thiazepine carboxylic acids esters and amides thereof
US4404137A (en) 1979-10-16 1983-09-13 Lilly Industries Limited Pyrazolo [3,4-b][1,5]benzodiazepine compounds
US4663453A (en) 1983-05-18 1987-05-05 Hoechst-Roussel Pharmaceuticals Inc. Benzo[b]pyrrolo[3,2,1-jk][1,4]benzodiazepines having dopamine receptor activity
US4764616A (en) * 1983-05-18 1988-08-16 Hoechst-Roussel Pharmaceuticals Inc. Benzopyrrolobenzodiazepines and quinobenzodiazepines
GB8607684D0 (en) 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
JPH04211071A (ja) 1990-03-05 1992-08-03 Hokuriku Seiyaku Co Ltd 多環式化合物
BE1004596A4 (fr) * 1990-09-26 1992-12-22 Therabel Res S A N V Derives de methylpiperazinoazepine, leur preparation et leur utilisation.
US5817655A (en) 1991-04-23 1998-10-06 Eli Lilly And Company Methods of treatment using a thieno-benzodiazepine
US5300422A (en) 1991-12-04 1994-04-05 Case Western Reserve University Screening method for controlling agranulocytosis
US5393752A (en) 1992-05-26 1995-02-28 Therabel Research S.A./N.V. Methylpiperazinoazepine compounds, preparation and use thereof
US5962664A (en) 1993-05-13 1999-10-05 Friedhoff; Arnold J. Psychosis protecting nucleic acid, peptides, compositions and method of use
US5354747A (en) 1993-06-16 1994-10-11 G. D. Searle & Co. 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9- and/or 10-substituted dibenzoxazepine and dibenzthiazepine compounds, pharmaceutical compositions and methods of use
IL110298A (en) 1993-07-13 1999-04-11 Brann Mark Robert Identification of ligands by selective amplification of cells transfected with receptors
US5538965A (en) 1993-12-23 1996-07-23 Allelix Biopharmaceuticals Inc. Dopamine receptor ligands
US6566065B1 (en) 1994-05-26 2003-05-20 Mcgill University Method of diagnosing schizophrenia by detecting a mutation in the (MTHFR) gene
GB2292685A (en) 1994-07-27 1996-03-06 Sankyo Co Allosteric effectors at muscarinic receptors
US5602124A (en) 1994-12-12 1997-02-11 Allelix Biopharmaceuticals, Inc. 5-HT2 receptor ligands
US5700445A (en) 1994-12-12 1997-12-23 Allelix Biopharmaceuticals, Inc. N-methyl piperazine compounds having dopamine receptor affinity
US5602120A (en) 1994-12-12 1997-02-11 Allelix Biopharmaceuticals, Inc. Benzyl-substituted compounds having dopamine receptor affinity
US5602121A (en) 1994-12-12 1997-02-11 Allelix Biopharmaceuticals, Inc. Alkyl-substituted compounds having dopamine receptor affinity
SE9500998D0 (sv) 1995-03-19 1995-03-19 Haakan Wilhelm Wikstroem New sulfone ester analogues of iso-clozapine and related structures: atypical neuroleptics
GB9617305D0 (en) 1996-08-17 1996-09-25 Glaxo Wellcome Spa Heterocyclic compounds
BR0110420A (pt) 2000-04-28 2003-07-01 Acadia Pharm Inc Agonistas muscarìnicos
AU2002249885A1 (en) 2000-11-17 2002-08-12 Adolor Corporation Delta agonist analgesics
CA2479932A1 (en) * 2002-03-28 2003-10-09 Eli Lilly And Company Piperazine substituted aryl benzodiazepines and their use as dopamine receptor antagonists for the treatment of psychotic disorders
BR0314108A (pt) 2002-09-18 2006-04-25 Fmc Corp derivados tricìclios inseticidas
EP1578198A1 (en) 2002-12-20 2005-09-28 Basf Aktiengesellschaft Pesticidal dibenzo(hetero)azepine derivatives
US20070275957A1 (en) 2003-01-23 2007-11-29 Weiner David M Use of n-desmethylclozapine to treat human neuropsychiatric disease
AU2004206931A1 (en) 2003-01-23 2004-08-05 Acadia Pharmaceuticals Inc. Use of N-desmethylclozapine to treat human neuropsychiatric disease
US20050250767A1 (en) 2003-01-23 2005-11-10 Weiner David M Use of N-desmethylclozapine to treat human neuropsychiatric disease
US20050085463A1 (en) 2003-01-23 2005-04-21 Weiner David M. Use of N-desmethylclozapine to treat human neuropsychiatric disease
WO2004073639A2 (en) 2003-02-19 2004-09-02 Merck & Co. Inc. Treatment of psychosis with a muscarinic m1 receptor ectopic activator
DE602004020263D1 (de) 2003-12-22 2009-05-07 Acadia Pharm Inc Amino-substituierte diaryläa,dücyclohepten- analoga als muscarinische agonisten und verfahren zur behandlung von neuropsychiatrischen erkrankungen
WO2005080976A1 (ja) 2004-02-20 2005-09-01 Dainippon Sumitomo Pharma Co., Ltd. 統合失調症の記憶・学習機能障害治療薬のin vivoスクリーニング方法
JP2007536216A (ja) 2004-04-01 2007-12-13 アカディア ファーマシューティカルズ，インコーポレーテッド 固体ｎ−デスメチルクロザピンおよびその結晶形を合成および単離する方法
US20060063754A1 (en) 2004-09-21 2006-03-23 Edgar Dale M Methods of treating a sleep disorder
JP5049129B2 (ja) 2004-09-21 2012-10-17 ハイプニオン・インコーポレイテッド ロキサピン類縁体およびそれらの使用方法
US20060252744A1 (en) 2005-04-04 2006-11-09 Burstein Ethan S Use of N-desmethylclozapine and related compounds as dopamine stabilizing agents
US20070105836A1 (en) 2005-10-31 2007-05-10 Lars Pettersson Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders

Also Published As

Publication number Publication date
PL1696931T3 (pl) 2009-10-30
EP1696931A2 (en) 2006-09-06
SI1696931T1 (sl) 2009-08-31
WO2005063254A2 (en) 2005-07-14
ATE426405T1 (de) 2009-04-15
CA2550735A1 (en) 2005-07-14
JP2007534656A (ja) 2007-11-29
ES2324713T3 (es) 2009-08-13
CN101962369A (zh) 2011-02-02
DK1696931T3 (da) 2009-06-29
US7491715B2 (en) 2009-02-17
EP2088147A1 (en) 2009-08-12
NZ547911A (en) 2010-06-25
US20100129473A1 (en) 2010-05-27
US20050192268A1 (en) 2005-09-01
US7517871B2 (en) 2009-04-14
CY1109171T1 (el) 2014-07-02
PT1696931E (pt) 2009-06-12
MXPA06007244A (es) 2006-08-18
AU2004308955A1 (en) 2005-07-14
AU2004308955B2 (en) 2011-08-04
US20060194784A1 (en) 2006-08-31
DE602004020263D1 (de) 2009-05-07
KR101157881B1 (ko) 2012-07-06
SG133606A1 (en) 2007-07-30
WO2005063254A3 (en) 2005-09-15
US7550454B2 (en) 2009-06-23
NO20063371L (no) 2006-09-22
US7622461B2 (en) 2009-11-24
US20070197502A1 (en) 2007-08-23
EP1696931B1 (en) 2009-03-25
BRPI0417749A (pt) 2007-04-10
KR20060128943A (ko) 2006-12-14
US20060199798A1 (en) 2006-09-07
IL176447A0 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
IL176447A0 (en) Amino substituted diaryl [a,d] cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
WO2008021463A3 (en) Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
WO2002074758A3 (en) Novel amines as histamine-3 receptor ligands and their therapeutic applications
ZA200501082B (en) Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
HK1145322A1 (es)
EG23719A (en) New process for the synthesis of (I S)-4,5-dimethoxy-1-(methylaminomethyl)-benzocyclobutane and addition salts thereof, and application in the synthesis of I V abradine and addition salts thereof witha pharmaceutically acceptable acid
AP2004003123A0 (en) Thiazole and oxazole derivatives that modulate PPAR activity
IL213649A0 (en) Prodrugs of gabapentin compounds, compositions and their use in the manufacture of a medicament
HK1163545A1 (en) Phenylpropionamide compounds and the use thereof
AU2003206413A8 (en) Substituted amino carboxamides for the treatment of alzheimer's disease
EP1449917A4 (en) PROCESS FOR PRODUCING L-AMINOACIDS USING ESCHERICHIA
EP1449918A4 (en) PROCESS FOR PRODUCING L-AMINOACIDS USING ESCHERICHIA
WO2004020431A3 (en) Novel benzoimidazole derivatives useful as antiproliferative agents
IL154470A0 (en) Use of derivatives of valproic acid amides and 2-valproenic acid amides for the treatment or prevention of pain and/or headache disorders
AP1791A (en) Amino acids with affinity for the ?2?-protein.
HK1050144A1 (en) Uses and compositions of nitrate esters for providing sedation.
WO2004026258A3 (en) Modulating vesicular monoamine transporter trafficking and function: a novel approach for the treatment of parkinson’s disease
WO2003057213A3 (en) Cyclohexano- and cycloheptapyrazole derivative compounds, for use in diseases associated with the 5-ht2c receptor
TW200511989A (en) Methods for using amino acids with affinity for the α 2 δ-protein
SI1619185T1 (sl) 4,4-difluoro-1,2,3,4-tetrahidro-5H-1-benzazepinski derivat ali njegova sol
BR0308753A (pt) Método para produzir pseudo-ilhotas
PL1716147T3 (pl) Pochodne diazaspiropiperydyny jako inhibitory transportera 1 glicyny i transportera 2 glicyny
FR2870732A1 (fr) Composition pour le traitement de matieres keratiniques comprenantun compose polycarboxylique particulier et un polymere cationique et procedes la mettant en oeuvre
CA2387394A1 (en) Use of 1-aminoindan derivatives for treatment of mania in bipolar mood disorder
ITPO20020002A1 (it) Macchina perfezionata per la produzione di catene "gourmette"

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20121221